

MD7510 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies (DL)

View Online



A Randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. (n.d.).
<http://www.journalslibrary.nihr.ac.uk/hta/volume-20/issue-64#abstract>

Amori, R. E., Lau, J., & Pittas, A. G. (2007). Efficacy and Safety of Incretin Therapy in Type 2 Diabetes. *JAMA*, 298(2). <https://doi.org/10.1001/jama.298.2.194>

Amy Kennedy. (2013). Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis. *PLoS ONE*, 8(3). <https://doi.org/doi:10.1371/journal.pone.0058861>

Anthony H. Barnett, Jenny Grice. (2013). *New Mechanisms in Glucose Control*. BMJ Books; 1 edition. <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics. (n.d.).
http://webarchive.nationalarchives.gov.uk/20080205132320/http://dh.gov.uk/en/publicationandstatistics/publications/publicationspolicyandguidance/dh_082200

Atkinson, M. A. (2012). The Pathogenesis and Natural History of Type 1 Diabetes. *Cold Spring Harbor Perspectives in Medicine*, 2(11), a007641–a007641.
<https://doi.org/10.1101/cshperspect.a007641>

Avery, L., Flynn, D., van Wersch, A., Sniehotta, F. F., & Trenell, M. I. (2012). Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. *Diabetes Care*, 35(12), 2681–2689.
<https://doi.org/10.2337/dc11-2452>

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 375(9733), 2223–2233.
[https://doi.org/10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2)

Bailey, Stephen. (n.d.). *Academic Writing: A Handbook for International Students*.
<http://lib.myilibrary.com.ezproxy4.lib.le.ac.uk/Open.aspx?id=310467>

Barry, V. W., Baruth, M., Beets, M. W., Durstine, J. L., Liu, J., & Blair, S. N. (2014). Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis. *Progress in Cardiovascular Diseases*, 56

(4), 382–390. <https://doi.org/10.1016/j.pcad.2013.09.002>

Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., Nicholson, W. K., Hutfless, S., Bass, E. B., & Bolen, S. (2011). Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. *Annals of Internal Medicine*, 154(9). <https://doi.org/10.7326/0003-4819-154-9-201105030-00336>

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., Willi, S. M., & Wood, M. A. (2010). Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*, 363(4), 311–320. <https://doi.org/10.1056/NEJMoa1002853>

Bethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., Peterson, E. D., & Holman, R. R. (2017). Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Care*, 40(4), 494–501. <https://doi.org/10.2337/dc16-1135>

Beverley M Shields. (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. *BMJ Open*, 5(11). <https://doi.org/doi:10.1136/bmjopen-2015-009088>

Birkeland, K. I. (2015). Hyperglycaemia in pregnancy: still a lot to learn. *The Lancet Diabetes & Endocrinology*, 3(10), 752–753. [https://doi.org/10.1016/S2213-8587\(15\)00282-X](https://doi.org/10.1016/S2213-8587(15)00282-X)

Brown, J., Alwan, N. A., West, J., Brown, S., McKinlay, C. J., Farrar, D., & Crowther, C. A. (1996). Lifestyle interventions for the treatment of women with gestational diabetes. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD011970.pub2>

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*, 154(2). <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>

Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., & Porter, L. E. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. *Diabetes Care*, 33(6), 1255–1261. <https://doi.org/10.2337/dc09-1914>

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *The Lancet*, 374(9683), 39–47. [https://doi.org/10.1016/S0140-6736\(09\)60659-0](https://doi.org/10.1016/S0140-6736(09)60659-0)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | 1-Recommendations | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ta390/chapter/1-Recommendations>

Capehorn, M., Polonsky, W. H., Edelman, S., Belton, A., Down, S., Gamerman, V., Nagel, F., Lee, J., & Alzaid, A. (2017). Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia). *Diabetic Medicine*. <https://doi.org/10.1111/dme.13357>

Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012). What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. *Diabetologia*, 55(3), 542–551. <https://doi.org/10.1007/s00125-011-2403-2>

Choudhary, P., Parrott, N. R., Birtles, L., & Rutter, M. K. (2012). Islet cell transplantation: current status in the UK (2012). *Practical Diabetes*, 29(7), 280–285. <https://doi.org/10.1002/pdi.1707>

Constructs of depression and distress in diabetes: time for an appraisal- ClinicalKey. (n.d.). <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858715001357>

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review) TA151, July 2008. (n.d.). <http://www.nice.org.uk/guidance/ta151>

Copeland, K. C., Silverstein, J., Moore, K. R., Prazar, G. E., Raymer, T., Shiffman, R. N., Springer, S. C., Thaker, V. V., Anderson, M., Spann, S. J., & Flinn, S. K. (2013). Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents. *PEDIATRICS*, 131(2), 364–382. <https://doi.org/10.1542/peds.2012-3494>

Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017). Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 10, 79–87. <https://doi.org/10.2147/DMSO.S126763>

Crete, P., & Lea, M. R. (2008). *Writing At University: A Guide For Students* (3rd ed). McGraw-Hill Education. <https://ebookcentral.proquest.com/lib/leicester/detail.action?pq-origsite=primo&docID=345134>

Dapagliflozin in combination therapy for treating type 2 diabetes June 2013. (n.d.). <http://www.nice.org.uk/guidance/ta288>

Davies, M., Dahl, D., Heise, T., Kiljanski, J., & Mathieu, C. (2017). Introduction of biosimilar insulins in Europe. *Diabetic Medicine*, 34(10), 1340–1353. <https://doi.org/10.1111/dme.13400>

Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Craddock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., Fox, C., Oliver, L., Rantell, K., Rayman, G., & Khunti, K. (2008). Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ*, 336(7642), 491–495. <https://doi.org/10.1136/bmj.39474.922025.BE>

Dhatariya, K. K., Skedgel, C., & Fordham, R. (2017). The cost of treating diabetic

ketoacidosis in the UK: a national survey of hospital resource use. *Diabetic Medicine*, 34 (10), 1361–1366. <https://doi.org/10.1111/dme.13427>

Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). (n.d.). <https://www.nice.org.uk/guidance/ng3>

Diagnosis and management of type 1 diabetes in children, young people and adults | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/cg15>

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*, 375 (9733), 2234–2243. [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0)

Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrback, J. L. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. *The Lancet*, 384(9951), 1349–1357. [https://doi.org/10.1016/S0140-6736\(14\)60976-4](https://doi.org/10.1016/S0140-6736(14)60976-4)

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis. (n.d.). <http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016). *New England Journal of Medicine*, 375(18), 1799–1802. <https://doi.org/10.1056/NEJMc1611290>

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes | Guidance and guidelines TA 248 Feb 2015. (n.d.). <https://www.nice.org.uk/guidance/ta248>

Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring. (n.d.). *Journal of Diabetes Science and Technology (Online)*, 3(4). <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>

Fagin, J. A., & Wells, S. A. (2016). Biologic and Clinical Perspectives on Thyroid Cancer. *New England Journal of Medicine*, 375(11), 1054–1067. <https://doi.org/10.1056/NEJMra1501993>

Ferrari, M., Dal Cin, M., & Steele, M. (2017). Self-compassion is associated with optimum self-care behaviour, medical outcomes and psychological well-being in a cross-sectional sample of adults with diabetes. *Diabetic Medicine*, 34(11), 1546–1553. <https://doi.org/10.1111/dme.13451>

Gale, E. A. (2013). Is type 2 diabetes a category error? *The Lancet*, 381(9881), 1956–1957. [https://doi.org/10.1016/S0140-6736\(12\)62207-7](https://doi.org/10.1016/S0140-6736(12)62207-7)

Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S., von Eynatten, M., Dugi, K. A., & Woerle, H.-J. (2012). 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *The Lancet*, 380(9840), 475–483.

[https://doi.org/10.1016/S0140-6736\(12\)60691-6](https://doi.org/10.1016/S0140-6736(12)60691-6)

Grammes, J., Stock, W., Mann, C. G., Flynn, E. M., & Kubiak, T. (2017). Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13506>

Gray, L. J., Khunti, K., Edwardson, C., Goldby, S., Henson, J., Morris, D. H., Sheppard, D., Webb, D., Williams, S., Yates, T., & Davies, M. J. (2012). Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. *Diabetologia*, 55(12), 3238–3244. <https://doi.org/10.1007/s00125-012-2725-8>

Gray, L. J., Khunti, K., Wilmot, E. G., Yates, T., & Davies, M. J. (2014). External validation of two diabetes risk scores in a young UK South Asian population. *Diabetes Research and Clinical Practice*, 104(3), 451–458. <https://doi.org/10.1016/j.diabres.2014.03.018>

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R. (2015). Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 373(3), 232–242. <https://doi.org/10.1056/NEJMoa1501352>

Gregg, E. W. (2017). The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016. *Diabetes Care*. <https://doi.org/10.2337/dci16-0055>

Guidelines. (n.d.).

<https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>

Hadjiconstantinou, M., Byrne, J., Bodicoat, D. H., Robertson, N., Eborall, H., Khunti, K., & Davies, M. J. (2016). Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. *Journal of Medical Internet Research*, 18(10). <https://doi.org/10.2196/jmir.5991>

Harman-Boehm, I. (2008). Continuous glucose monitoring in type 2 diabetes. *Diabetes Research and Clinical Practice*, 82, S118–S121. <https://doi.org/10.1016/j.diabres.2008.09.051>

Hartman, Y. A. W., Jansen, H. J., Hopman, M. T. E., Tack, C. J., & Thijssen, D. H. J. (2017). Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior. *Diabetes Care*, 40(9), e120–e121. <https://doi.org/10.2337/dc17-0787>

Heinonen, I., Helajärvi, H., Pakkala, K., Heinonen, O. J., Hirvensalo, M., Pälve, K., Tammelin, T., Yang, X., Juonala, M., Mikkilä, V., Kähönen, M., Lehtimäki, T., Viikari, J., & Raitakari, O. T. (2013). Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study. *BMJ Open*, 3(6). <https://doi.org/10.1136/bmjopen-2013-002901>

Henson, Joseph. (2014). Associations of Sedentary Time with Fat Distribution in a High-Risk Population. <https://lra.le.ac.uk/handle/2381/32505>

Hessler, D. M., Fisher, L., Polonsky, W. H., Masharani, U., Strycker, L. A., Peters, A. L., Blumer, I., & Bowyer, V. (2017). Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. *Diabetic Medicine*, 34(9), 1228–1234. <https://doi.org/10.1111/dme.13381>

Holt, R. I. G. (2010a). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010b). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010c). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010d). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010e). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010f). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010g). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010h). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010i). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G. (2010j). *Textbook of diabetes* (4th ed). Wiley-Blackwell.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016a). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016b). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016c). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016d). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

- Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016e). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>
- Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016f). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>
- Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016g). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>
- Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016h). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>
- Holt, R. I. G., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2016i). *Textbook of Diabetes* (5th ed). John Wiley & Sons, Incorporated.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 38(1), 140–149. <https://doi.org/10.2337/dc14-2441>
- Jelinek, H. F., Stranieri, A., Yatsko, A., & Venkatraman, S. (2016). Data analytics identify glycosylated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. *Computers in Biology and Medicine*, 75, 90–97. <https://doi.org/10.1016/j.combiomed.2016.05.005>
- John M Jakicic. (2005). Physical activity considerations for the treatment and prevention of obesity. *The American Journal of Clinical Nutrition*, 82(1), 226S-229S.
<http://ajcn.nutrition.org/content/82/1/226S>
- Johnston, B. C., Kanters, S., Bandayrel, K., Wu, P., Naji, F., Siemieniuk, R. A., Ball, G. D. C., Busse, J. W., Thorlund, K., Guyatt, G., Jansen, J. P., & Mills, E. J. (2014). Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults. *JAMA*, 312(9). <https://doi.org/10.1001/jama.2014.10397>
- Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C-peptide measurement in the care of patients with diabetes. *Diabetic Medicine*, 30(7), 803–817.
<https://doi.org/10.1111/dme.12159>
- Kamlesh Khunti. (2015). Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. *PLoS ONE*, 10(9). <https://doi.org/doi:10.1371/journal.pone.0135702>
- Kenneth Hodson. (2010). Gestational diabetes: emerging concepts in pathophysiology. *Obstetric Medicine*, 3(4). <https://doi.org/doi:10.1258/om.2010.100025>
- Latika Sahu. (2009). Comparison of the American Diabetes Association and World Health

Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy. *Obstetric Medicine*, 2(4). <https://doi.org/doi: 10.1258/om.2009.080049>

Lee, I.-M. (2010). Physical Activity and Weight Gain Prevention. *JAMA*, 303(12). <https://doi.org/10.1001/jama.2010.312>

Leelarathna, L., Roberts, S. A., Hindle, A., Markakis, K., Alam, T., Chapman, A., Morris, J., Urwin, A., Jinadev, P., & Rutter, M. K. (2017). Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*, 34(10), 1372–1379. <https://doi.org/10.1111/dme.13412>

Leff, D. R., & Heath, D. (2009). Surgery for obesity in adulthood. *BMJ*, 339(sep22 1), b3402–b3402. <https://doi.org/10.1136/bmj.b3402>

Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 10, 123–139. <https://doi.org/10.2147/DMSO.S130834>

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016). *New England Journal of Medicine*, 375(18), 1797–1799. <https://doi.org/10.1056/NEJMc1611289>

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. (n.d.-a). <https://www.nice.org.uk/guidance/ta203>

Liraglutide for the treatment of type 2 diabetes mellitus. TA203, Oct 2010. (n.d.-b). <https://www.nice.org.uk/guidance/ta203>

Managing Older People with Type 2 Diabetes: IDF Global Guideline - International Federation on Ageing. (n.d.). <https://www.ifa-fiv.org/managing-older-people-with-type-2-diabetes-idf-global-guideline/>

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJMoa1607141>

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016a). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016b). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 311–322. <https://doi.org/10.1056/NEJMoa1603827>

Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. CG76, Jan 2009. (n.d.). <https://www.nice.org.uk/guidance/cg76>

- Merlin C. Thomas. (2016). Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. *Diabetes Therapy*, 7(3).
<https://doi.org/doi:10.1007/s13300-016-0189-4>
- Min, S. H., Yoon, J.-H., Hahn, S., & Cho, Y. M. (2017). Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. *Diabetes/Metabolism Research and Reviews*, 33(1).
<https://doi.org/10.1002/dmrr.2818>
- Minimizing Hypoglycemia in Diabetes: Table 1. (2015). *Diabetes Care*, 38(8), 1583–1591.
<https://doi.org/10.2337/dc15-0279>
- Mishriky, B. M., Cummings, D. M., & Tanenberg, R. J. (2015). The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*, 109(2), 378–388. <https://doi.org/10.1016/j.diabres.2015.05.025>
- Moreno-Castilla, C., Mauricio, D., & Hernandez, M. (2016). Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus. *Current Diabetes Reports*, 16(4). <https://doi.org/10.1007/s11892-016-0717-7>
- Narendran, P., Jackson, N., Daley, A., Thompson, D., Stokes, K., Greenfield, S., Charlton, M., Curran, M., Solomon, T. P. J., Nouwen, A., Lee, S. I., Cooper, A. R., Mostazir, M., Taylor, R. S., Kennedy, A., & Andrews, R. C. (2017). Exercise to preserve β -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. *Diabetic Medicine*, 34(11), 1521–1531. <https://doi.org/10.1111/dme.13439>
- National Obesity Observatory. (n.d.). <http://www.noo.org.uk>
- Nauck, M. A., & Meier, J. J. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *The Lancet Diabetes & Endocrinology*, 4(6), 525–536.
[https://doi.org/10.1016/S2213-8587\(15\)00482-9](https://doi.org/10.1016/S2213-8587(15)00482-9)
- Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., & Stein, P. P. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity and Metabolism*, 9(2), 194–205. <https://doi.org/10.1111/j.1463-1326.2006.00704.x>
- Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care*, 37(8), 2149–2158.
<https://doi.org/10.2337/dc13-2761>
- NHS Evidence: an introduction. (n.d.). http://www.solent.nhs.uk/_store/documents/nhs_evidence_guide.pdf
- Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *New England Journal of Medicine*, 356(24), 2457–2471. <https://doi.org/10.1056/NEJMoa072761>

- Noctor, E., & Dunne, F. (2015). Postnatal testing following gestational diabetes. *The Lancet Diabetes & Endocrinology*, 3(10), 761–762.
[https://doi.org/10.1016/S2213-8587\(15\)00322-8](https://doi.org/10.1016/S2213-8587(15)00322-8)
- Nolan, C. J., Ruderman, N. B., Kahn, S. E., Pedersen, O., & Prentki, M. (2015). Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. *Diabetes*, 64(3), 673–686.
<https://doi.org/10.2337/db14-0694>
- Obesity: identification, assessment and management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/cg189>
- Paul Craddy. (2014). Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. *Diabetes Therapy*, 5 (1). <https://doi.org/doi:10.1007/s13300-014-0061-3>
- Perrin, N. E., Davies, M. J., Robertson, N., Snoek, F. J., & Khunti, K. (2017). The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*, 34(11), 1508–1520.
<https://doi.org/10.1111/dme.13448>
- Persaud, S. J., & Jones, P. M. (2016). A Wake-up Call for Type 2 Diabetes? *New England Journal of Medicine*, 375(11), 1090–1092. <https://doi.org/10.1056/NEJMcibr1607950>
- Pickup, J. C. (2012). Insulin-Pump Therapy for Type 1 Diabetes Mellitus. *New England Journal of Medicine*, 366(17), 1616–1624. <https://doi.org/10.1056/NEJMcibr1113948>
- Qin, L., Knol, M. J., Corpeleijn, E., & Stolk, R. P. (2010). Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data. *European Journal of Epidemiology*, 25(1), 5–12. <https://doi.org/10.1007/s10654-009-9395-y>
- Rasouli, B., Andersson, T., Carlsson, P.-O., Hjort, R., Löfvenborg, J. E., Martinell, M., Groop, L., Tuomi, T., & Carlsson, S. (2017). Serious life events and the risk of latent autoimmune diabetes in adults (LADA) and Type 2 diabetes. *Diabetic Medicine*, 34(9), 1259–1263.
<https://doi.org/10.1111/dme.13410>
- Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*, 36(9), 2489–2496.
<https://doi.org/10.2337/dc12-2454>
- Rinki Murphy. (2015). Monogenic diabetes and pregnancy. *Obstetric Medicine*, 8(3).
<https://doi.org/doi:10.1177/1753495X15590713>
- Rizos, C. V., Kei, A., & Elisaf, M. S. (2016). The current role of thiazolidinediones in diabetes management. *Archives of Toxicology*, 90(8), 1861–1881.
<https://doi.org/10.1007/s00204-016-1737-4>
- Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2015). Implications of incretin-based therapies on cardiovascular disease. *International Journal of Clinical Practice*, 69(5),

531-549. <https://doi.org/10.1111/ijcp.12572>

Ryder, B., McKnight, J., Blann, A., Dhatariya, K., Gregory, R., Robinson, T., Rowles, S., Sharp, P., Winocour, P. H., & Walton, C. (2013). ABCD position statement on GLP-1 based therapies and pancreatic damage. *Practical Diabetes*, 30(9), 388-391. <https://doi.org/10.1002/pdi.1816>

S M Attard. (2015). Implications of iron deficiency/anemia on the classification of diabetes using HbA1c. *Nutrition & Diabetes*, 5(6). <https://doi.org/doi:10.1038/nutd.2015.16>

Sallis, J. F., Bull, F., Guthold, R., Heath, G. W., Inoue, S., Kelly, P., Oyeyemi, A. L., Perez, L. G., Richards, J., & Hallal, P. C. (2016). Progress in physical activity over the Olympic quadrennium. *The Lancet*, 388(10051), 1325-1336. [https://doi.org/10.1016/S0140-6736\(16\)30581-5](https://doi.org/10.1016/S0140-6736(16)30581-5)

Samuel, V. T., & Shulman, G. I. (2012). Integrating Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell*, 148(5), 852-871. <https://doi.org/10.1016/j.cell.2012.02.017>

Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017a). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*, 376(7), 641-651. <https://doi.org/10.1056/NEJMoa1600869>

Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., & Kashyap, S. R. (2017b). Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. *New England Journal of Medicine*, 376(7), 641-651. <https://doi.org/10.1056/NEJMoa1600869>

Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012). Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes. *New England Journal of Medicine*, 366(17), 1567-1576. <https://doi.org/10.1056/NEJMoa1200225>

Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016). The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema. *Diabetes Care*, 39(2), 179-186. <https://doi.org/10.2337/dc15-1585>

Sivasubramaniam, S., Amiel, S. A., & Choudhary, P. (2017). Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range. *Diabetic Medicine*, 34(10), 1456-1460. <https://doi.org/10.1111/dme.13438>

Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., Sullivan, M., & Wedel, H. (2004). Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *New England Journal of Medicine*, 351(26), 2683-2693. <https://doi.org/10.1056/NEJMoa035622>
Srinivasan, P., Huang, G. C., Amiel, S. A., & Heaton, N. D. (2007). Islet cell transplantation. *Postgraduate Medical Journal*, 83(978), 224-229. <https://doi.org/10.1136/pgmj.2006.053447>

Standards of Medical Care in Diabetes--2015: Summary of Revisions. (2015). *Diabetes Care*, 38(Supplement_1), S4-S4. <https://doi.org/10.2337/dc15-S003>

Steven, S., Hollingsworth, K. G., Al-Mrabeh, A., Avery, L., Aribisala, B., Caslake, M., & Taylor, R. (2016). Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care*, 39(5), 808–815. <https://doi.org/10.2337/dc15-1942>

Steven, S., & Taylor, R. (2015). Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes. *Diabetic Medicine*, 32(9), 1149–1155. <https://doi.org/10.1111/dme.12722>

Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., & Murphy, H. R. (2016). Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *New England Journal of Medicine*, 375(7), 644–654. <https://doi.org/10.1056/NEJMoa1602494>

Tanner, M. (2016). Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia. *Annals of Internal Medicine*, 165(4). <https://doi.org/10.7326/ACPJC-2016-165-4-020>

Tao, L., Wilson, E. C. F., Wareham, N. J., Sandbaek, A., Rutten, G. E. H. M., Lauritzen, T., Khunti, K., Davies, M. J., Borch-Johnsen, K., Griffin, S. J., & Simmons, R. K. (2015). Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. *Diabetic Medicine*, 32(7), 907–919. <https://doi.org/10.1111/dme.12711>

The Eatwell Guide. (2016). Public Health England. <https://www.gov.uk/government/publications/the-eatwell-guide>

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ng28>

Type 2 diabetes: lixisenatide | Evidence-review | Advice | NICE. (n.d.). <https://www.nice.org.uk/advice/esnm26/chapter/evidence-review>

Type 2 diabetes: prevention in people at high risk | Guidance and guidelines | NICE. (n.d.). <http://www.nice.org.uk/guidance/PH38>

Umpierre, D. (2011). Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes. *JAMA*, 305(17). <https://doi.org/10.1001/jama.2011.576>

Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care. (n.d.). <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*, 34(9), 1205–1211.

<https://doi.org/10.1111/dme.13379>

Vloemans, A. F., van Beers, C. A. J., de Wit, M., Cleijne, W., Rondags, S. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Serné, E. H., & Snoek, F. J. (2017). Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. *Diabetic Medicine*, 34(10), 1470–1476. <https://doi.org/10.1111/dme.13429>

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016). Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*, 375(4), 323–334. <https://doi.org/10.1056/NEJMoa1515920>

William H. Polonsky, Lawrence Fisher, Jay Earles, R. James Dudl, Joel Lees, Joseph Mullan. (n.d.). Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. *Diabetes Care*.
http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=25&docId=GALE%7CA130282980&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GAL E%7CA130282980&searchId=R15&userGroupName=leicester&inPS=true
Yates, T., & Davies, M. J. (2017). Physical activity and Type 1 diabetes: an underused therapy. *Diabetic Medicine*, 34(11), 1498–1499. <https://doi.org/10.1111/dme.13445>

Yeh, J. S., Kushner, R. F., & Schiff, G. D. (2016). Obesity and Management of Weight Loss. *New England Journal of Medicine*, 375(12), 1187–1189. <https://doi.org/10.1056/NEJMclde1515935>

Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2017). Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140. *Diabetes Care*, 40(2), 287.1–287. <https://doi.org/10.2337/dc17-er02>

Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016). Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. *Postgraduate Medical Journal*, 92(1084), 63–69. <https://doi.org/10.1136/postgradmedj-2015-133281>